Narcolepsy | Treatment Algorithms: Claims Data Analysis | US | 2025
Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability of many pharmacological treatments, a large proportion of patients have inadequate control of their narcolepsy symptoms, leaving opportunity for new agents to address these shortcomings. Given that narcolepsy treatment is highly individualized and complex, understanding the use of current therapies in the nuanced treatment algorithm ahead of anticipated product launches is essential. Our Treatment Algorithms research leverages national patient-level claims data to explore the uptake and use of key therapies in narcolepsy (such as modafinil, armodafinil, psychostimulants, antidepressants) and agents approved for the treatment of EDS, or EDS and cataplexy symptoms in narcolepsy (such as Harmony Biosciences’ Wakix, Axsome Therapeutics’ Sunosi, Jazz Pharmaceuticals’ Xyrem and Xywav, and Avadel Pharmaceuticals’ Lumryz) in both newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed narcolepsy patients?
- How have branded agents such as Harmony Biosciences’ Wakix, Axsome Therapeutics’ Sunosi, Jazz Pharmaceuticals’ Xyrem and Xywav, and Avadel Pharmaceuticals’ Lumryz been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of narcolepsy patients receive drug therapy within four years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within four years of diagnosis?
- What percentage of narcolepsy patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: armodafinil, modafinil, Sunosi, Vyvanse (including its generics), Xyrem, Xywav, Wakix, Lumryz
Key companies covered: Axsome, Avadel Pharmaceuticals, Eli Lilly, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, Teva
Key analysis provided:
- Brand / therapy usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
KEY FEATURE
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
